Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 65Neoplasm Metastasis 14Brain Neoplasms 10Neoplasms 9Endometrial Neoplasms 8Prostatic Neoplasms 7Glioblastoma 7Ovarian Neoplasms 6Triple Negative Breast Neoplasms 5Glioma 5Sarcoma 3Recurrence 3Neoplasms by Site 3Meningioma 3Carcinoma, Non-Small-Cell Lung 3Breast Diseases 3Unilateral Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Osteosarcoma 2Liposarcoma 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Ependymoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Advanced Breast Cancer 2Venous Thromboembolism 1Uterine Cervical Neoplasms 1

Interventions

abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fibrocystic Breast Disease × abemaciclib × 1 year × Clear all
NCT03979508 2025-11-12

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Mayo Clinic

Phase 2 Terminated
26 enrolled
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡